Stereotactic radiosurgery alone for patients with 1-4 radioresistant brain metastases.
Brain metastases from radioresistant histologies are perceived to be less responsive to WBRT compared to other histologies, and stereotactic radiosurgery (SRS) may provide better local control. The aim of this study was to examine the outcomes of patients with 1-4 brain metastasis from radioresistant histologies (renal cell carcinoma and melanoma) treated with SRS alone. Thirty-eight patients with 1-4 radioresistant brain metastases (66 lesions) were treated with SRS alone. The median age was 55 years. Fourteen and 24 patients had renal cell carcinoma (RCC) and melanoma brain metastases, respectively. Distribution of number of lesions was as follows: one lesion, 22 patients; 2 lesions, 8 patients; 3 lesions, 5 patients; and 4 lesions, 3 patients. Distribution of RTOG recursive partitioning analysis (RPA) classes was as follows: II, 37 patients and III, 1 patient. The median marginal dose was 20 Gy. The median follow-up was 6.1 months. The 3-, 6-, 9-, 12-, and 18-month local control (LC) rates were 87.9, 81.4, 67.9, 67.9, and 60.3%, respectively. The corresponding free-from-distant-brain failure (FFDBF) rates were 71.3, 58.1, 49.8, 40.2, and 27.6%. The corresponding progression-free survival (PFS) rates were 55.3, 41.9, 33, 23.3, and 13.3%. RCC histology was associated with better LC (P = 0.0055). Although SRS alone could yield reasonable LC in patients with 1-4 radioresistant brain metastases, the risk of distant brain failure was substantial. The approach of routine omission of WBRT outside of a trial setting should be used judiciously.
Lo
Simon S
SS
Department of Radiation Oncology, Arthur G. James Cancer Hospital, Ohio State University Medical Center, 300 West 10th Avenue, Ste 088A, Columbus, OH 43210, USA. Simon.Lo@osumc.edu
Clarke
James W
JW
Grecula
John C
JC
McGregor
John M
JM
Mayr
Nina A
NA
Cavaliere
Robert
R
Kendra
Kari L
KL
Gupta
Nilendu
N
Wang
Jian Z
JZ
Sarkar
Atom
A
Olencki
Thomas E
TE
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001932:Brain Neoplasms / Q000401:mortality / Q000532:radiotherapy* / Q000556:secondary*; D016371:Cranial Irradiation / Q000009:adverse effects / Q000379:methods; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D016634:Radiosurgery / Q000009:adverse effects / Q000379:methods*; D012189:Retrospective Studies; D015996:Survival Rate
Neurosurgery. 2005 May;56(5):936-45; discussion 936-45
15854241
Lancet Oncol. 2009 Nov;10(11):1037-44
19801201
N Engl J Med. 1990 Feb 22;322(8):494-500
2405271
J Clin Oncol. 2005 Dec 1;23(34):8870-6
16314647
JAMA. 2006 Jun 7;295(21):2483-91
16757720
Lancet. 2004 May 22;363(9422):1665-72
15158627
Int J Radiat Oncol Biol Phys. 2004 Jul 15;59(4):1097-106
15234044
Int J Radiat Oncol Biol Phys. 2000 Jul 1;47(4):1007-12
10863072
Expert Rev Neurother. 2005 Jul;5(4):487-95
16026232
Acta Neurochir (Wien). 1998;140(6):549-55
9755321
Neurology. 1989 Jun;39(6):789-96
2725874
Int J Radiat Oncol Biol Phys. 2007 Aug 1;68(5):1388-95
17674975
Cancer. 1998 Jul 15;83(2):344-53
9669818
Int J Radiat Oncol Biol Phys. 2002 Apr 1;52(5):1277-87
11955740
Int J Radiat Oncol Biol Phys. 1999 Sep 1;45(2):427-34
10487566
Int J Radiat Oncol Biol Phys. 1997 Aug 1;39(1):25-30
9300736
Neurol Clin. 2003 Feb;21(1):1-23, vii
12690643
J Neurosurg. 2002 Mar;96(3):544-51
11883840
Anticancer Res. 2007 Nov-Dec;27(6C):4255-7
18214028
Int J Radiat Oncol Biol Phys. 1998 Oct 1;42(3):581-9
9806518